Purple Innovation Reports Second Quarter 2026 Results

Purple Innovation, Inc. (PRPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Purple Innovation Reports Second Quarter 2026 Results Showroom Revenue Up 16.6% and Comparable Revenue Up 18% GAAP Net Loss of $3.2 Million in the Second Quarter Adjusted EBITDA Improves $4.4 Million to $2.1 Million Regains Compliance with Nasdaq Minimum Bid Price Re

Original reporting
Published Aug 10, 2026, 8:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PRPL
Neutral
medium confidence
Mentioned
$PRPL
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PRPLNeutralMed
01

Why it matters

The key tradable elements are the lowered revenue guidance range, the improved Adjusted EBITDA, and the closure of the Nasdaq minimum bid price deficiency matter.

02

Market read

This is a company-specific earnings and guidance update with a compliance overhang removed, but with weaker wholesale and a reduced revenue outlook.

03

What to watch

Wholesale decline is attributed partly to higher customer/manufacturer payments and lower volume; traders may need to separate pricing/mix effects from volume and working-capital impacts.

Relevance 7/10Novelty 8/10Timing: after-hours filing and same-day earnings call (Aug 10, 2026)

Background

Purple filed an 8-K with its Q2 2026 results and a press release, including a Nasdaq listing compliance update and full-year outlook.

Company-level read

Ticker impact

$PRPLNeutralMedium confidence
Context

Purple reported Q2 results and lowered 2026 revenue guidance to $420M-$440M while improving Adjusted EBITDA to $2.1M.

Expected impact

Near-term volatility likely as investors weigh weaker wholesale and lower revenue guidance against improved adjusted EBITDA and bid-price compliance.

Evidence & confidence

The filing discloses multiple decision-relevant datapoints: revenue down 6.5% YoY, wholesale down 19.1%, Adjusted EBITDA up to $2.1M, and a full-year revenue range reduction with a maintained EBITDA target range.

Market effects

Signals ongoing demand softness in wholesale for mattress retailers while DTC showrooms remain a relative bright spot.

Limited direct regional spillover; primarily company-specific comfort retail dynamics.

Low global relevance; tariff refund benefit is a localized margin swing rather than a broad macro driver.

Counterpoint

The tariff-refund-driven gross margin lift and marketing reclassification may overstate underlying demand strength; wholesale weakness could reassert quickly.

Key entities

  • Purple Innovation, Inc.

    Comfort innovation company reporting Q2 2026 results, lowering FY revenue guidance, and regaining Nasdaq minimum bid compliance.

  • Nasdaq Stock Market LLC

    Confirmed Purple regained compliance with Nasdaq Listing Rule 5450(a)(1), closing the bid-price deficiency matter.

Related articles

$PRPLMed

Purple Innovation Reports Third Quarter 2026 Results

Purple Innovation, Inc. (PRPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONFIDENTIAL DRAFT Purple Innovation Reports Third Quarter 2026 Results Positive Operating Cash Flow for the Third Consecutive Quarter Preparing for Major Mattress Portfolio Refresh to Strengthen Performance in 2027 Lehi, Utah, November 4, 2026 – Purple Innovation, I

$PRPLMedAI 8/10

Why Purple (PRPL) Stock Is Trading Lower Today

Purple (PRPL) shares fell 24.6% after the company reported Q2 revenue of $98.27 million, down 6.5% year over year and below Wall Street expectations. Adjusted EPS was a loss of $1.52, better than forecast. Purple kept full-year revenue guidance around $430 million, but investors focused on the quarterly sales miss.

$PRPLMedAI 8/10

Purple (NASDAQ:PRPL) Misses Q2 CY2026 Sales Expectations

Purple (NASDAQ:PRPL) reported Q2 CY2026 revenue of $98.27 million, down 6.5% year on year, missing market expectations. Non-GAAP adjusted EPS was -$1.52, better than analysts’ consensus. For next quarter, management guided revenue to $430 million at the midpoint. The article also notes negative operating margin and ongoing revenue decline.

Med

TELUS (TU) Q3 2026 Earnings Call Transcript

TELUS (TU) outlined three key priorities during its Q3 2026 earnings call: strengthening its financial foundation, honing operational discipline, and deploying resources for growth. The company aims to reduce debt, achieve a net debt to adjusted EBITDA leverage ratio of 3x or lower by 2028, and target $900 million in annualized cash savings by 2028. TELUS plans to monetize non-core assets, streamline operations, and invest in its PureFibre network for growth in AI infrastructure.

$PAHCMedAI 8/10

Phibro Animal (PAHC) Q1 2027 Earnings Call Transcript

Phibro Animal Health (PAHC) reported Q1 2027 sales growth of 6% to $386.8M and adjusted EBITDA growth of 4% to $64.3M. Performance Products and Mineral Nutrition segments drove growth, while Animal Health saw a 3% increase. The company maintained its full-year guidance and expects protein demand to grow, despite near-term pressure on producer profitability.

$NOGMed

Northern Oil And Gas (NOG) Beat Expectations, But Is The Stock Still Cheap?

Northern Oil and Gas (NOG) reported record Q3 production and EBITDA, beating earnings expectations. The company raised its 2026 output guidance. Despite a 19.44% drop in the 7-day share price, the 1-year return is 14.36% and the 5-year return is 22.67%. The stock is trading at $22.84, with some analysts valuing it at $30.44, suggesting a 25% undervaluation. The company's focus on capital allocation and asset mix aims to support future earnings.